Active ingredients:

Lisinopril Dehydrate - 5 mg, 10 mg or 20 mg.

LIPRIL is a peptidyl dipeptidase inhibitor. It inhibits the angiotensin converting enzyme (ACE) that catalyses the conversion of angiotensin I to the vasoconstrictor peptide, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased concentrations of angiotensin II which results in decreased vasopressor activity and reduced aldosterone secretion. The latter decrease may result in an increase in serum potassium concentration. Whilst the mechanism through which lisinopril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, lisinopril is antihypertensive even in patients with low renin hypertension. ACE is identical to kininase II, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodilatory peptide, play a role in the therapeutic effects of lisinopril remains to be elucidated.

Indications

• essential hypertension;
• symptomatic heart failure;
• acute myocardial infarction: Short-term (6 weeks) treatment of haemodynamically stable patients within 24 hours of an acute myocardial infarction;
• renal complications of diabetes mellitus: Treatment of renal disease in hypertensive patients with Type 2 diabetes mellitus and incipient nephropathy.

Dosage and pharmaceutical form:

tablets 5 mg, 10 mg or 20 mg; 10 tablets in blister, 3 blisters in package; 60 tablets in container and package; 90 tablets in container and package.

Another products:

Liprazide 10

Liprazide 20